For Healthcare Professionals

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment


About the study

The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin's lymphoma (cHL). Eligible patients are children, adolescents, and young adults relapsed or refractory to first line.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Classic Hodgkin Lymphoma (cHL), relapsed or refractory
  2. Minimal limitation on activities of daily living as measured by Karnofsky ≥ 50 for participants > 16 years of age or Lansky ≥ 50 for participants ≤ 16 years of age.
  3. One prior anti-cancer therapy that did not work


Exclusion Criteria:

  1. Active, known, or suspected autoimmune disease or infection
  2. Active cerebral/meningeal disease related to the underlying malignancy
  3. More than one line of anti-cancer therapy or no treatment at all
  4. Received a stem cell transplant for Hodgkin Lymphoma and/or a solid organ transplant
  5. Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)

Other protocol defined inclusion/exclusion criteria apply

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Hodgkin Disease

Age (in years)

5 - 30


Phase 2

Participants needed


Est. Completion Date

Nov 10, 2024

Treatment type



Bristol-Myers Squibb identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.